PV Bulletin
PvBulletin
Home /Regulators/TGA safety updates add warnings for GLP-1s, fluoroquinolones, RSV vaccines
RegulatorsTgaAustralia

TGA safety updates add warnings for GLP-1s, fluoroquinolones, RSV vaccines

TGA safety updates in 2025 describe warning/label changes for GLP-1/dual agonists, fluoroquinolone antibiotics, and RSV vaccines Arexvy/Abrysvo, with PI/CMI alignment implications in Australia.

PV Impact Brief

Urgency: MediumConfidence: medium
Relevant for
Local Safety OfficerSignal Management LeadLabeling LeadRegulatory Intelligence LeadPV Quality LeadQPPV
Processes impacted
Label GovernanceSignal ValidationRisk ManagementLocal Affiliate ComplianceSignal DetectionRegulatory Intelligence Monitoring
Action needed

Tga update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.

Owner

Local Safety Officer

Review cadence

Review in the next governance cycle and track weekly until closure.

Evidence and confidence

Confidence: mediumSource update date not verified — confirm on the regulator site before acting

Primary-source confirmation recommended before operational implementation.

Full briefing

What changed

TGA safety updates in 2025 describe warning/label changes for GLP-1/dual agonists, fluoroquinolone antibiotics, and RSV vaccines Arexvy/Abrysvo, with PI/CMI alignment implications in Australia.

Why it matters

Potential impact spans Label Governance, Signal Validation, Risk Management, Local Affiliate Compliance, Signal Detection, Regulatory Intelligence Monitoring, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Practical implication

Tga update requires triage for Label Governance, Signal Validation, Risk Management; confirm local obligations and document follow-up actions.

#Labeling#Signal Management#Risk Management#Country Compliance#TGA#Label Update#Drug Safety#Medicines#Vaccines

Related updates for your role

RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

Regulatory action
Public Notification
Tawon Liar
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsFDAUSA

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Regulatory action
Class 2 Device Recall
PhaseOne Antimicrobial Solution · Oculus Technologies of Mexico, S.A. de C.V.
Lot/batch: 25G263
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief →
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief →
TGA safety updates add warnings for GLP-1s, fluoroquinolones, RSV vaccines | PV Bulletin